E2XA34 logo

Exact Sciences CorporationBOVESPA:E2XA34 Stock Report

Market Cap R$106.7b
Share Price
R$43.90
n/a
1Y23.8%
7D0%
Portfolio Value
​
View

Exact Sciences Corporation

BOVESPA:E2XA34 Stock Report

Market Cap: R$106.7b

Exact Sciences (E2XA34) Stock Overview

Provides cancer screening and diagnostic test products in the United States and internationally. More details

E2XA34 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Earnings are forecast to grow 82.79% per year

Risk Analysis

Shares are highly illiquid


E2XA34 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Exact Sciences Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Exact Sciences
Historical stock prices
Current Share PriceUS$43.90
52 Week HighUS$43.90
52 Week LowUS$20.94
Beta1.42
1 Month Change0%
3 Month Changen/a
1 Year Change23.84%
3 Year Change62.59%
5 Year Changen/a
Change since IPO8.23%

Recent News & Updates

Recent updates

Shareholder Returns

E2XA34BR BiotechsBR Market
7D0%2.3%-0.1%
1Y23.8%22.6%19.3%

Return vs Industry: E2XA34 exceeded the BR Biotechs industry which returned 22.6% over the past year.

Return vs Market: E2XA34 exceeded the BR Market which returned 19.3% over the past year.

Price Volatility

Is E2XA34's price volatile compared to industry and market?
E2XA34 volatility
E2XA34 Average Weekly Movementn/a
Biotechs Industry Average Movement9.1%
Market Average Movement4.5%
10% most volatile stocks in BR Market9.0%
10% least volatile stocks in BR Market1.6%

Stable Share Price: E2XA34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine E2XA34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19956,950Kevin Conroywww.exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer.

Exact Sciences Corporation Fundamentals Summary

How do Exact Sciences's earnings and revenue compare to its market cap?
E2XA34 fundamental statistics
Market capR$106.71b
Earnings (TTM)-R$5.46b
Revenue (TTM)R$17.07b
6.3x
P/S Ratio
-19.5x
P/E Ratio

Is E2XA34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E2XA34 income statement (TTM)
RevenueUS$3.08b
Cost of RevenueUS$942.43m
Gross ProfitUS$2.14b
Other ExpensesUS$3.13b
Earnings-US$986.58m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.20
Gross Margin69.42%
Net Profit Margin-32.01%
Debt/Equity Ratio93.0%

How did E2XA34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/25 07:38
End of Day Share Price 2025/11/19 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exact Sciences Corporation is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Bruce JacksonBenchmark Company